446880-84-8Relevant academic research and scientific papers
ALK5 INHIBITOR CONJUGATES AND USES THEREOF
-
Paragraph 0176; 0183-0185, (2021/07/17)
The present disclosure relates to targeted drug conjugates comprising ALK5 inhibitors and targeting moieties that direct the ALK5 inhibitors to cells involved in fibrosis and cancer, for example myofibroblasts, activated fibroblasts and transitioning fibr
ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
-
Paragraph 0168; 0175-0177, (2020/02/06)
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
-
Paragraph 0184; 0191-0193, (2020/06/07)
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
-
Paragraph 0173; 0180-0182, (2021/01/21)
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS
-
Page 63-64, (2010/02/06)
This invention relates to novel 2-phenylpyridin-4-yl heterocyclyl derivatives which are inhibitors of the transforming growth factor, ("TGF")-? signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.
PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR
-
Page 20, (2010/02/06)
The invention relates to novel pyrazole derivatives of formula (I), which are inhibitors of the transforming growth factor, ("TGF")-? signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.
